These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20364670)

  • 1. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].
    Barkhaleva OA; Ladyzhenskaia IP; Vorob'eva MS; Shalunova NV; Podcherniaeva RIa; Mikhaĭlova GR; Khorosheva TV; Barinskiĭ IF
    Vopr Virusol; 2009; 54(5):33-7. PubMed ID: 19882901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
    Mastrolorenzo A; Tiradritti L; Salimbeni L; Zuccati G
    Int J STD AIDS; 1995; 6(6):431-5. PubMed ID: 8845402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenge of developing a herpes simplex virus 2 vaccine.
    Dropulic LK; Cohen JI
    Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
    Awasthi S; Friedman HM
    J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
    [No Abstract]   [Full Text] [Related]  

  • 7. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ; Mindel A
    Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A killed commercial vaccine against herpes simplex viruses 1 and 2 as an immunocorrective agent in chronic herpetic infection].
    Barinskiĭ IF; Kasparov AA; Lazarenko AA; Alimbarova LM; Davydova AA; Belkina IV; Platonova AL
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):98-102. PubMed ID: 10876868
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus type 2 vaccines: new ground for optimism?
    Aurelian L
    Clin Diagn Lab Immunol; 2004 May; 11(3):437-45. PubMed ID: 15138167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in herpes simplex virus vaccine development: notes from the battlefield.
    Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L
    Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
    Jones CA; Cunningham AL
    Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.
    Morello CS; Levinson MS; Kraynyak KA; Spector DH
    J Virol; 2011 Apr; 85(7):3461-72. PubMed ID: 21270160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology. Painful failure of promising genital herpes vaccine.
    Cohen J
    Science; 2010 Oct; 330(6002):304. PubMed ID: 20947733
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.